13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • UpFrontPSMA

    Acronym: 

    ACTRN/NCT /ethics: 

    Scientific title: 

    UpFrontPSMA : A Randomised Phase 2 Study of Sequential 177Lu- PSMA617 and Docetaxel versus Docetaxel in Metastatic Hormone-Naive Prostate Cancer

    Summary of trial and patient characteristics

    Cancer Type Prostate
    Trial Type Treatment
    Phase Phase II Tumour Stream Prostate
    Age Range Cancer Stage Metastatic or Widespread
    Sex Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Prostate
    Trial Type Treatment
    Phase Phase II
    Age Range
    Sex
    Molecular Target
    Tumour Stream Prostate
    Cancer Stage Metastatic or Widespread
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    UpFrontPSMA : A Randomised Phase 2 Study of Sequential 177Lu- PSMA617 and Docetaxel versus Docetaxel in Metastatic Hormone-Naive Prostate Cancer

    Lay Summary

    UpFrontPSMA : A Randomised Phase 2 Study of Sequential 177Lu- PSMA617 and Docetaxel versus Docetaxel in Metastatic Hormone-Naive Prostate Cancer

    Sponsor / Cooperative group

    ANZUP

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Royal Adelaide Hospital Anne Milton anne.milton@sa.gov.au 08 7074 2342 Dr Hsiang Tan Not Yet Recruiting